Literature DB >> 26846956

Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial.

Tannas Jatene, Robert A Harrington, Gregg W Stone, Ph Gabriel Steg, C Michael Gibson, Christian W Hamm, Matthew J Price, Jayne Prats, Efthymios N Deliargyris, Kenneth W Mahaffey, Harvey D White, Deepak L Bhatt.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26846956     DOI： 10.1016/j.jacc.2015.11.027

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  6 in total

1.  Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).

Authors:  Matthew A Cavender; Deepak L Bhatt; Gregg W Stone; Harvey D White; Ph Gabriel Steg; C Michael Gibson; Christian W Hamm; Matthew J Price; Sergio Leonardi; Jayne Prats; Efthymios N Deliargyris; Kenneth W Mahaffey; Robert A Harrington
Journal:  Circulation       Date:  2016-08-01       Impact factor: 29.690

2.  Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY).

Authors:  Sergio Leonardi; Anna Franzone; Raffaele Piccolo; Eugene McFadden; Pascal Vranckx; Patrick Serruys; Edouard Benit; Christoph Liebetrau; Luc Janssens; Maurizio Ferrario; Aleksander Zurakowski; Robert-Jan van Geuns; Marcello Dominici; Kurt Huber; Ton Slagboom; Paweł Buszman; Leonardo Bolognese; Carlo Tumscitz; Krzysztof Bryniarski; Adel Aminian; Mathias Vrolix; Ivo Petrov; Scot Garg; Christoph Naber; Janusz Prokopczuk; Christian Hamm; Gabriel Steg; Dik Heg; Peter Juni; Stephan Windecker; Marco Valgimigli
Journal:  BMJ Open       Date:  2019-03-09       Impact factor: 2.692

3.  The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX.

Authors:  Celina M Yong; Vandana Sundaram; Freddy Abnousi; Christoph B Olivier; Jaden Yang; Gregg W Stone; Philippe G Steg; C Michael Gibson; Christian W Hamm; Matthew J Price; Efthymios N Deliargyris; Jayne Prats; Harvey D White; Robert A Harrington; Deepak L Bhatt; Kenneth W Mahaffey
Journal:  Clin Cardiol       Date:  2019-06-29       Impact factor: 2.882

4.  Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.

Authors:  Matthew A Cavender; Robert A Harrington; Gregg W Stone; Ph Gabriel Steg; C Michael Gibson; Christian W Hamm; Matthew J Price; Renato D Lopes; Sergio Leonardi; Efthymios N Deliargyris; Jayne Prats; Kenneth W Mahaffey; Harvey D White; Deepak L Bhatt
Journal:  Circ Cardiovasc Interv       Date:  2021-12-17       Impact factor: 7.514

5.  Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients.

Authors:  Florian Prüller; Lukasz Bis; Oliver Leopold Milke; Friedrich Fruhwald; Sascha Pätzold; Siegfried Altmanninger-Sock; Jolanta Siller-Matula; Friederike von Lewinski; Klemens Ablasser; Michael Sacherer; Dirk von Lewinski
Journal:  J Clin Med       Date:  2018-11-15       Impact factor: 4.241

6.  Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.

Authors:  Ivar S Jensen; Elizabeth Wu; Philip L Cyr; Marc Claussen; Thomas Winkler; Khalid Salahuddin; Jayne Prats; Kenneth W Mahaffey; Charles Michael Gibson; Philippe Gabriel Steg; Gregg W Stone; Deepak L Bhatt
Journal:  Am J Cardiovasc Drugs       Date:  2021-07-31       Impact factor: 3.571
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.